Claritev Corp

Claritev Corp(CTEV)股票分析

$39.390

+0.618 (+1.57%)收盤時

Loading chart…
High
39.646
Open
38.060
VWAP
38.96
Vol
132.98K
Mkt Cap
Low
37.850
Amount
5.18M
EV/EBITDA, TTM
9.02

Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.

AI analysis of Claritev Corp (CTEV)

buy

Claritev Corporation (CTEV) appears to be a good buy right now due to its recent positive earnings report showing a narrower loss of $59.23 million compared to $62.64 million last year, and a revenue growth of 6.6% year-over-year to $257.48 million. Additionally, the stock has a forward P/E ratio of 6.47, indicating potential undervaluation. However, the main risk is the ongoing antitrust investigation which has contributed to a significant 37% drop in stock price this year, indicating market uncertainty.

估值指標

The current forward P/E ratio for Claritev Corp (CTEV) is 6.47, compared to its 5-year average forward P/E of -1.36.

Forward P/E

Strongly Overvalued
5Y Average P/E
-1.36
Current P/E
6.47
高估
2.51
低估
-5.24

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
9.28
Current EV/EBITDA
9.02
高估
9.94
低估
8.63

Forward P/S

Fair
5Y Average P/S
0.59
Current P/S
0.62
高估
0.86
低估
0.31

Alphio AI Price Scenarios for CTEV

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CTEV

$27.94

情境價格

B

Base

Base · 50%CTEV

$26.34

情境價格

B

Bear

Bear · 25%CTEV

$21.83

情境價格

Whales holding CTEV

T

The Public Investment Fund of The Kingdom of Saudi Arabia

+ HoldingCTEV

-6.37%

3M Return

事件時間軸

2026-08-07 (ET)

05:30:00

Company Raises FY26 Adjusted EBITDA Outlook to $620M

05:30:00

Claritev Q2 Revenue Reaches $257.48M, Exceeds Expectations

2026-07-14 (ET)

13:30:00

Justice Department Expands Antitrust Investigation into Claritev

13:30:00

DOJ Expands Antitrust Investigation into Claritev

13:30:00

Claritev Shares Drop 13% to $25.93 Following Bloomberg Report

資訊

CTEV FAQ — answered by Alphio AI

Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors. It operates in the Industrials sector.

Claritev Corporation (CTEV) appears to be a good buy right now due to its recent positive earnings report showing a narrower loss of $59.23 million compared to $62.64 million last year, and a revenue growth of 6.6% year-over-year to $257.48 million. Additionally, the stock has a forward P/E ratio of 6.47, indicating potential undervaluation. However, the main risk is the ongoing antitrust investigation which has contributed to a significant 37% drop in stock price this year, indicating market uncertainty.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始